LX1001
LX1001-02
Phase 1 mab active
Quick answer
LX1001 for Alzheimer Disease is a Phase 1 program (mab) at Lexeo Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Lexeo Therapeutics
- Indication
- Alzheimer Disease
- Phase
- Phase 1
- Modality
- mab
- Status
- active